Kamada reports Q1 2026 results and affirms 2026 guidance
Revenue rose 3% to $45.2 million, adjusted EBITDA was $11.6 million, and net income increased 4% to $4.1 million.
See the latest news and media coverage for Kamada. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global specialty plasma-derived biopharmaceutical company
kamada.comLast updated
In short: Kamada reported Q1 2026 growth, reaffirmed its annual guidance, and secured FDA approval for a major plasma collection center in San Antonio.
Revenue rose 3% to $45.2 million, adjusted EBITDA was $11.6 million, and net income increased 4% to $4.1 million.
The center can collect 50,000 liters annually and generate an estimated US$8-10 million in revenue. It is one of the largest specialty plasma centers and will seek EMA approval.
The dividend is part of an annual policy to distribute at least 50% of net income, payable on April 6, 2026.
It forecasts $200–$205M revenue and $50–$53M adjusted EBITDA, affirms 2025 guidance, and reports approximately $75M year-end cash.
Kamada (KMDA) earnings outlook covers AI demand, revenue acceleration, and growth forecasts with daily analyst insights and growth expectations. Kamada Ltd. (KMDA) reported earnings per...
Kamada Ltd. (NASDAQ:NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ETCompany ParticipantsBrian Ritchie - Investor Relations,...
Moby summary of Kamada Ltd.'s Q1 2026 earnings call...
Kamada Ltd () has held its Q4 earnings call. Read on for the main highlights of the call. End of Quarter Sale - 50% Off...
Track Kamada and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Kamada and other trending companies.